ADXS - Ayala Pharma to continue Phase 2/3 Ringside study in desmoid tumors

• Ayala Pharmaceuticals ( OTCQX:ADXS ) announces that the Independent Data Monitoring Committee (IDMC) for its Phase 2/3 RINGSIDE study evaluating AL102 in desmoid tumors conducted a prespecified periodic review of data and recommended that the study continue without modifications.
• The primary endpoint for Phase 3 RINGSIDE trial, which will enroll up to 156 patients is progression-free survival with secondary endpoints including objective response rate, duration of response, tumor volume reduction, and patient-reported Quality of Life measures.
• Desmoid tumors, also called aggressive fibromatosis, are rare connective tissue tumors that typically arise in the upper and lower extremities, abdominal wall, head and neck area, mesenteric root, and chest wall, or other parts of the body.

For further details see: